GSK, FDA fight diet-pill fakes

Drug giant GlaxoSmithKline is fighting counterfeiters who have targeted its over-the-counter weight-loss product, Alli. The fakes contain sibutramine rather than the drug's active ingredient, orlistat, says the FDA. Suspicions arose early last month through consumer complaints. Internet sales so far are the only retail channel involved.

Sibutramine, a schedule 4 controlled substance, is itself an appetite-suppressant. Ukmedix News reports that many orlistat takers use the drug because they cannot tolerate the sibutramine-containing Reductil treatment made by Abbott Labs. Sibutramine can lead to harmful interactions with other medications.

The FDA warns that the fake looks similar to the real thing, but has some differences not likely to be noticed by consumers. Among them are the missing lot codes, slightly outsized bottle cap, lack of inner seal protection declaration, and powder-, rather than pellet-filled capsules. The FDA site includes comparative photos.

See the FDA announcement
Here's the Ukmedix News report

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.